UGANDA NATIONAL TUBERCULOSIS AND LEPROSY CONTROL …E Plan... · necessitated revisions to the current NTLP National Strategic Plan (NSP) 2015/16 to 2019/20. Accordingly, the NTLP

MINISTRY OF HEALTH

UGANDA NATIONAL TUBERCULOSIS AND LEPROSY

CONTROL PROGRAMME

Revised Strategic Plan 2015/16 - 2019/20

Monitoring and Evaluation Plan

Narrative of the Operational, Budget and

Technical Assistance Plan

June 2017

Uganda NTLP Rev. National Strategic Plan 2015/16 – 2019/20 | Monitoring & Evaluation | 2

TABLE OF CONTENTS

1. Introduction 3

Overview of the NTLP M&E System 3

Data Collection Methods 4

2. Monitoring and Evaluation Plan 5

M&E Plan Objectives 5

Indicators by objective and strategic intervention 6

Indicator definitions 27

3. Narrative of the Operational, Budget and Technical Assistance Plan 42


1. Introduction

Tuberculosis (TB) and leprosy continue to threaten public health in Uganda. The Ugandan

Ministry of Health addresses TB and leprosy response in its Health Sector Development Plan II

2015/2016 – 2019/20. TB is the fifth most common cause of death in Uganda, potentially

resulting in adverse socioeconomic impacts as the majority of notified patients/cases are in their

years of greatest economic productivity. Leprosy is still endemic in Uganda. A total of 1,003 new

cases were reported to NTLP during the last 3 years. In 2013, over 60% of new cases were

concentrated in 10 of 116 districts.

Recent advances in the fight against TB and leprosy, findings from the 2014/15 National TB

Prevalence Survey, and revisions to the Uganda Xpert MTB/Rif policy and urban DOTS model

necessitated revisions to the current NTLP National Strategic Plan (NSP) 2015/16 to 2019/20.

Accordingly, the NTLP revised the monitoring and evaluation (M&E) plan to reflect changes in

the strategic plan 2015/16 – 2019/20.

Overview of the NTLP M&E System

The goal of the current M&E plan is to enable evidence-based decision-making to improve

performance. Based on this, the M&E plan sets out to:

Guide the process of collecting, analysing and presenting specific data, based on pre-

defined indicators;

Describe and guide the process of measuring progress towards NTLP targets;

Ensure the set of indicators, tools and M&E systems are adapted to monitor the quality

and coverage of service delivery, both at health facility and community levels;

Ensure effective implementation of the M&E plan by regularly monitoring and

periodically evaluating the plan itself; and

Provide a framework for implementation of NTLP monitoring and evaluation activities.

The WHO and MOH joint review of the NTLP conducted in September 2013 revealed that NTLP

reports are not channelled through the Electronic Health Information System, Uganda’s District

Health Information System 2 (DHIS2). Managed by the MOH Division of Health Information, the

DHIS2 has a user-friendly interface and 100% health facility reporting coverage for the public

and private non-for-profit sectors.

Although health facilities are reporting some TB indicators through DHIS2, these reports are

often incomplete and inaccurate hence not analysed or used. More so, the TB indicators have

not been completely integrated into the DHIS2. The only indicators in DHIS 2 are; proportion of

PLHIV screened for active TB; proportion of PLHIV diagnosed with TB and proportion of PLHIV

diagnosed with TB who are started on TB treatment.

A disadvantage of the DHIS2 is that it aggregates data, preventing individual data for cohort

analysis. The NTLP is still investigating how to integrate TB data collection and management in

the DHIS2 while providing for the NTLP’s data needs (List of the proposed indicators to be

included in DHIS2 is in Table 4).

Table 1 provides an overview of the current NTLP reports and data sources.


Table 1: Description of NTLP reports and data sources.

Data Source Relevant Time

Period

Frequency of

Collection

Responsibility

National TB

Prevalence Survey

2014-2015 Every 5-10 years NTLP & Partners

NTP reports and

WHO Global

Tuberculosis Report

Previous year Annually NTLP, WHO

NTP quarterly reports Previous quarter Quarterly NTLP

EQA quarterly

reports

Previous quarter Quarterly National TB

Reference

Laboratory (NTRL)

TB services in prisons

reports

Previous quarter Quarterly Prison Health

Service

Supervisory visit

reports

Previous quarter Quarterly for

selected districts

NTLP, NTRL

Data Collection Methods

The routine reporting system follows these lines of reporting:

Diagnostic and Treatment Units (DTU) report to the district.

Districts report to regions.

Regions report to the central NTLP office.

Currently, the M&E unit at the central NTLP office consists of an M&E specialist, epidemiologist,

data manager and data analyst. The M&E specialist and data manager, funded through the Global

Fund to Fight AIDS, TB, and Malaria (Global Fund), collate and analyse data from the districts.

Partners provide additional staff to support the NTLP’s efforts to improve recording, reporting

and use of TB data at all levels of the health system.

As recommended in the Program Review Report (September 2013), the NTLP is developing

standard operating procedures (SOPs) to guide health facilities as well as district, regional and

national level officers to improve data completeness, quality and use for performance

improvement at different levels. In addition, quarterly review meetings help to improve the

accuracy of data and timeliness of reporting.

During regional quarterly review meetings, district supervisors (District TB and Leprosy

Supervisors (DTLS), District laboratory Focal Persons (DLFP) verify outcomes of TB patients

transferred from one district to another within the region and Regional TB and Leprosy Focal

Persons (RTLPs) validate the reports before submission to the national level. The district local

governments have recruited biostatisticians to improve collection, analysis and use of health

information at the district level. The biostatisticians will support the district TB supervisors to

improve timely reporting through the DHIS2 and analysis of TB data for performance

improvement.


2. Monitoring and Evaluation Plan

This M&E plan aims to monitor the TB and leprosy control, implementation of the NSP 2015/16

– 2019/20, and investments to improve M&E for TB and leprosy in Uganda.

M&E Plan Objectives

Objectives of the M&E component of the NSP

The NTLP National Strategic Plan prioritizes M&E in its fourth objective “to establish and

strengthen systems for effective management of tuberculosis & leprosy services to meet the

NSP targets.”

Broad Objective

To establish and strengthen M&E systems for tracking performance and measuring outcomes

and impacts to guide decision-making

Specific Objectives

1. Improve recording and reporting, data management and analytical capacity

at national and sub-national levels

2. Develop an electronic TB monitoring and evaluation system (eTB)

3. Strengthen TB supervision at all levels

Under the same objective, the National Strategic Plan calls for implementation of a research

agenda through collaboration of NTLP and the Uganda TB research community. This

intervention includes a drug resistant survey and inventory studies to assess under-reporting, to

be conducted in the 2015/16 – 2019/20 period.

The NSP M&E intervention aims to strengthen data management and quality through by

regularly assessing data quality and developing guidelines and standard operating procedures.

To improve timely availability of data, NTLP plans to develop an electronic system that will

capture more data as well, for example of key populations, by of this NSP. To support these

developments, NTLP will strengthen supervision to all levels.

Table 2: Main activities under the M&E strategic intervention

Start

date

M/Year

End

date

M/Year

Indicator Target

by

2019/20

Total investment

Objective 4: To strengthen systems for effective management of tuberculosis & leprosy services to

meet the NSP targets

Strategic Intervention 4.7. To strengthen M&E systems for tracking performance and measuring

outcomes and impacts to guide decision-making


4.7.1. Improve recording and

reporting, data management

and analytical capacity at

national and sub-national

levels.

Apr-16 Jun-20 4.7.1

Percentage of

districts

submitting

timely

complete

reports

according to

national

guidelines

(factor =

timeliness x

completeness)

>90% $5,280,167

4.7.2. Develop electronic TB

monitoring and evaluation

system (eTB).

Oct-15 Jun-20 $649,060

4.7.3. Strengthen TB

supervision at all levels.

Jul-15 Jun-20 $1,089,382

Total Investment M & E $7,018,608

Indicators by objective and strategic intervention

Figure 1 illustrates the monitoring framework to track progress of TB control and NSP

implementation in Uganda.

Figure 1. TB monitoring framework

Through a consultative process, stakeholders set initial targets in June - July 2014. The NTLP

modified these targets during revisions to the National Strategic Plan, according to 2014/15

National TB Prevalence Survey results and revisions to the Uganda Xpert MTB/Rif policy and

urban DOTS model and recommendations from local, international and global technical

partners.


Goal: To reduce TB incidence by 5%, i.e. from 234 cases of TB (all forms) per 100,000 population in 2015 to 222/100,000 by 2020

Indicator Type Baseline Targets Data

source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20

1.0 Incidence rate Impact 2015 234 234 234 230 227 222

Uganda

national

TB survey

Annual

Objective 1: To increase case notification rate of incident TB from 119/100,000 in 2015/16 to 156/100,000 in 2019/20 and to

increase treatment success rate among notified incident cases from 74% in 2015/16 to 85% in 2019/20


source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20

1.1. Notification

rate of incident

TB cases per

100,000

population

Outcome

2015

119

(42,320)

119

(42,320)

115

(42,320)

128

(48,245)

141

(54,999)

156

(62,699)

TB annual

&

quarterly

reports

Annual

1.2. Treatment

success rate for

incident TB cases

(Denominator)

Outcome 2015

cohort

74%

(42,320)

74%

(42,320)

78%

(42,320)

82%

(42,320)

85%

(48,245)

85%

(54,699)

TB

quarterly

reports

Quarterly

1.3. Cure rate

among new PBC

TB cases

Outcome 2015

cohort 51% 51% 56% 60% 65% 75%

TB

quarterly

reports

Quarterly

1.4. Treatment

success rate

among all forms

of TB

Outcome 2015

cohort 79% 79% 80% 82% 84% 85%

TB

quarterly

reports

Quarterly



source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20

1.5. Case fatality

rate among all

forms of TB

Outcome 2015

cohort <5% <5% <5% <5% <5% <5%

TB

quarterly

reports

Quarterly

1.6. Loss to

follow-up rate

among all forms

of TB

Outcome 2015

cohort 12% 12% <5% <5% <5% <5%

TB

quarterly

reports

Quarterly

Strategic intervention 1.1: Increase the capacity of health workers to screen and diagnose TB, with a focus on childhood, extra-pulmonary and

clinically diagnosed TB.


source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20

1.1.1. Percentage of

children (0-14

years) among all

forms of incident

TB patients notified

Output 2015 7.4%

(3,132)

7.4%

(3,132)

9%

(3,809)

11%

(5,307)

13%

(7,150)

15%

(8,935)

TB

quarterly

reports

Quarterly

Strategic intervention 1.2: Improve access to and use of quality laboratory and radiology services for TB diagnosis and treatment monitoring.


source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20

1.2.1. Number of

new pulmonary

bacteriologically

confirmed patients

notified

Output 2015

cohort 25,382 25,382 25,382 28,778 32,807 37,400

TB quarterly

reports Quarterly



source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20


new and relapse TB

patients tested

using WHO

recommended

rapid tests at time

of diagnosis

Output 2015 21% 21% 26% 36% 46% 56% TB quarterly

reports Annual

1.2.3. Drug

susceptibility

testing coverage

(%)

Output 2015 25% 25% 31% 41% 51% 61% TB quarterly

reports Annual


labs participating in

external quality

assurance (EQA)

Output 2015 88% 88% 90% 92% 94% 96%

National

and

regional

quarterly

EQA reports

Annual

1.2.5. The

percentage of high

false negative

reported in

diagnostic and

treatment units

Output 2015 3% 3% < 3% < 2% < 2% < 2%

National

and

regional

quarterly

EQA reports

Annual

Strategic intervention 1.3: Register and initiate treatment with all diagnosed TB patients, and support their adherence to treatment regimens.


source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20

1.3.1. TB treatment

coverage in %

(Denominator)

Output 2015 51%

(83,380)

51%

(83,380)

49%

(85,958)

55%

(87,209)

62%

(88,479)

70%

(89,310)

Annual

report Annual



source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20

1.3.2. Proportion of

all TB patients

registered in care

who are treated

under Directly

Observed Therapy

(DOT)

Output 2015 77% 77% 77% 80% 85% 90%

TB

Quarterly

report

Quarterly

Strategic intervention 1.4: Empower patients, their families and communities to recognise and refer presumptive TB patients to diagnostic

facilities, support treatment adherence and conduct contact tracing


source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20


TB cases (all forms)

notified in the

diagnostic and

treatment units

who were referred

by the village

health team/CSO

Output Unknown 7%

(42,320)

8%

(42,320)

9%

(48,245)

10%

(54,999)

11%

(62,699)

VHT

registers,

CSO/CBO

reports

Annual

1.4.2. Contact

investigation

coverage

Output 2015 3% 8% 13% 20% 28% 35% Unit TB

register Quarterly

1.4.3. Contact

investigation

coverage among

PBC-TB cases

Output 2015 14% 14% 14% 24% 34% 50% Unit TB

register Quarterly



source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20

1.4.4. Number of

close contacts

(<5years) of PTB

patients provided

IPT

Output 2015 831 831 1,122 2,026 3,937 7,070

TB

quarterly

reports

Quarterly

1.4.5. Latent TB

treatment (IPT)

coverage ( <5years

contacts of PTB

patients)

Output 2015 8% 8% 18% 28% 38% 50%

TB

quarterly

reports

Annual

Strategic intervention 1.5: Establish and strengthen facility and community health systems to facilitate referral of presumptive TB patients to diagnostic

facilities as well as support treatment adherence and systematic TB screening among contacts (CHEWs, CLFs and VHTs).


source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20

1.5.1 Proportion of

mapped CSOs that

are implementing

TB control activities

Output 2013 Unknown 10% 10% 15% 20% 25% URSB

directory Annual

1.5.2 Proportion of

mapped CSO’s

reporting using

recommended

tools

Output 2013 Unknown 10% 10% 20% 35% 50%

CHEWs/

VHT

register

Quarterly

1.5.3 Proportion of

mapped CSOs

trained in TB

management

Output 2013 Unknown 10% 10% 60% 65% 70%

NTLP

training

reports

Annual


Strategic intervention 1.6: Strengthen TB care and prevention in congregate settings.


source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20

1.6.1. Percentage

new prisoners

screened for TB

(entry screening)

Output 2013 55% 60% 65% 70% 75% 80%

Prison

health

services

reports

Quarterly

1.6.2. Number

bacteriological

confirmed TB in

new prisoners

Output 2013 91 169 186 205 224 243

Prison

health

services

reports

Annual

Strategic intervention 1.7: Strengthen and expand public-private mix approaches for TB care and control, in line with the national policy framework.


source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20

1.7.1. Number of

private for-private

& private not-for-

profit health

facilities accredited

to function as

diagnostic and

treatment units

Output 2015 100 100 326 400 500 600 Surveys Annual


Strategic intervention 1.8: Implement an urban TB care and prevention strategy for cities and municipalities.


source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20

1.8.1. Treatment

success rate for

incident TB cases

on first-line drugs

in cities and

municipalities

Output 2015

cohort 87% 87% 88% 89% 90% 90% DHIS 2 Annual

1.8.2. Contact

investigation

coverage in cities &

municipalities

Output 2015 28% 28% 40% 50% 60% 70% DHIS 2 Annual

1.8.3. Number of

close contacts

(<5years) of PTB

patients provided

IPT in cities &

municipalities

Output 2015 376 376 537 671 806 950 DHIS 2 Quarterly

1.8.4. Latent TB

treatment (IPT)

coverage (<5years

contacts of PTB

patients) in cities &

municipalities

Output 2015 17% 17% 25% 35% 45% 60% DHIS 2 Annual


Objective 2: To strengthen TB/HIV integrated care for co-infected patients and increase ART coverage among TB/HIV co-infected among

TB/HIV co-infected patients from 88% in 2015/16 to 95% by 2019/20

Note: These indicators and targets are aligned with the Uganda TB/HIV policy (2013).


source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20

2.1. Percentage of

registered

incident TB

patients co-

infected with HIV

who started on

and/or continued

anti-retroviral

therapy (ART)

(Denominator)

Outcome 2015 88%

(17,088)

88%

(17,088)

90%

(17,211)

92%

(20,022)

94%

(22,825)

95%

(26,020)

TB

quarterly

reports

Quarterly

Strategic intervention 2.1: Strengthen collaboration, coordination and monitoring mechanisms for TB/HIV integration.


source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20

2.1.1. Percentage

of TB/HIV joint

planning meetings

held

Output 2015 Unknown 25% 50% 75% 100% 100%

Minutes

of

meetings

Annual


Strategic intervention 2.2: Scale up implementation of the one-stop model for co-infected TB patients at health facilities.


source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20

2.2.1. Percentage

of health centres

(IV and above)

providing TB/HIV

services in an

integrated manner

Output 2015 Unknown 5% 10% 25% 50% 70%

Surveys,

supervision

reports,

DQA

Annual

Strategic intervention 2.3: Implement TB/HIV interventions to decrease the burden of HIV among patients with presumptive and diagnosed TB.


source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20


registered new and

relapse TB patients

with documented

HIV status

Output 2015

97%

(42,320)

97%

(42,320)

98%

(42,320)

99%

(48,245)

100%

(54,999)

100%

(62,699)

TB

quarterly

reports

Quarterly


registered HIV-

positive TB patients

who started on

and/or continued

co-trimoxazole

preventive

treatment (CPT)

Output 2015

98%

(17,088)

98%

(17,088)

99%

(17,211)

99%

(20,022)

99%

(22,825)

99%

(26,020)

TB

quarterly

reports

Quarterly


Strategic intervention 2.4: Support implementation of Intensified Case Finding (ICF) i.e. active TB case finding among people living with HIV and provision

of IPT in HIV care clinics.


source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20

2.4.1. Percentage

of people living

with HIV who were

newly enrolled in

HIV care and

screened for TB

Output 2015 68% 68% 75% 80% 90% 95% HMIS

106a Annual

2.4.2. Latent TB

treatment

coverage among

newly enrolled

people living with

HIV

Output 2015 Unknown Unknown 5% 10% 20% 30% HMIS

106a Annual

Strategic intervention 2.5: Implement TB infection control (TBIC) practices in all health care facilities, congregate and community settings.


source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20

2.5.1. Number of

health workers

diagnosed with TB

in the last year

Output 2015 Unknown 93 83 73 63 53

unit TB

register

&

quarterly

report

Annual

2.5.2. Percentage

of prisoners

screened for TB in

the last year

Output 2015 2015 15% 25% 40% 50% 60% HMIS

106a Annual


Objective 3: To increase case detection rate of MDR/RR/-TB from 17% in 2015/16 to 51% in 2019/20 and raise the treatment success rate from

74% in 2015/16 to 80% by 2019/20


source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20

3.1. Number and

percentage of

detected

MDR/RR-TB

patients among

estimated

MDR/RR TB

cases

Outcome 2015 401

17%

401

17%

498

21%

780

32%

1,041

42%

1,278

51%

TB

quarterly

reports, Lab

reports

Quarterly

3.2. Treatment

success rate for

MDR/RR-TB

cases

Outcome 2015 74% 74% 75% 76% 78% 80%

DR-TB

surveillance

system

Annual

Strategic intervention 3.1: Ensure early detection of MDR/RR/-TB.


source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20


previously treated

TB patients tested

for MDR TB with

documented

Genexpert MTB/Rif

or culture result

Output 2015 65% 65% 73% 80% 87% 95%

TB

quarterly

reports

Quarterly



source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20


close contacts of

MDR/RR-TB

patients traced and

screened for TB at

least once

Output 2015 96% 96% 97% 98% 99% 100%

DR-TB

unit

registers

Quarterly

Strategic intervention 3.2: Ensure early initiation of treatment and improve the quality of care for MDR/RR-TB patients.

Strategic intervention 3.3: Expand access to and improve MDR/RR/-TB patient management (including home-based care for patients unable to visit a

follow-up facility).


source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20

3.3.1. Number of

functional MDR/RR-

TB treatment

initiation sites

Output 2015

15

15

16 17 18 19

DR-TB

surveillance

system

Quarterly


source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20

3.2.1 Number (%)

of confirmed DR-TB

cases started on

DR-TB treatment

Output 2015 311

(78%)

311

(78%)

398

(80%)

663

(85%)

937

(90%)

1214

(95%)

DR-TB

surveillanc

e system

Quarterly


Strategic intervention 3.4: Implement Infection control practices in all MDR/RR/-TB treatment initiation and follow-up facilities as well as in communities.

Indicator Type Baseline Targets

Data source Frequency Year Value 2015/16 2016/17 2017/18 2018/19 2019/20

3.4.1. Number of

health workers

diagnosed with DR-

TB in the previous

one year

Output 2015 0 0 <5 <5 <5 <5 Annual

assessments Annual

Strategic intervention 3.5: Strengthen data management, monitoring and evaluation of MDR-TB care.


source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20


MDR/RR-TB

treatment facilities

submitting timely,

complete reports

according to

national guidelines

Output 2015 Unknown Unknown >90% 100% 100% 100% NTLP

DHIS2 Quarterly


Objective 4: To strengthen systems for effective management of tuberculosis and leprosy services to meet the NSP targets

Strategic intervention 4.1: Advocate for increased financial resources from domestic sources and ensure efficient and effective use of available finances.


source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20


the NTLP annual

budget funded by

government

Output 2015 4% 4% 6% 9% 12% 15% NTLP

central unit Annual


TB affected

households that

experience

catastrophic costs

due to TB

Output 2015 Unknown Unknown

30%

[Update

after

survey]

25% 20% 10% NTLP

central unit Annual

Strategic intervention 4.2: Engage communities and stakeholders in TB and leprosy prevention and care.


source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20

4.2.1. New

community TB and

leprosy groups

active in TB and

leprosy care

Output 2015 20 25 35 45 55 65 USTP

reports annual


Strategic intervention 4.3: Improve human resource capacity at all levels to effectively deliver TB and leprosy services.


source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20

4.3.1. Proportion of

filled positions in

the NTLP human

resources structure

Output 2015 33% 33% 40% 45% 50% 50%

NTLP

annual

report

Annual

Strategic intervention 4.5: Improve the quality of TB care and ensure patient safety at all levels.


source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20


initial loss to follow

up

Output 2015 11% 11% 8% <5% <5% <5%

DQA

report,

surveys

Quarterly

4.5.2. Loss to follow

up rate for notified

cases

Output 2015 11% 11% 9% 5% <5% <5%

TB

quarterly

reports

Quarterly

Strategic intervention 4.6: Improve availability of quality assured TB and leprosy medicines, supplies and equipment at all levels.


source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20


treatment units

reporting no stock

outs of anti-TB

medicines in the

last 3 months

before assessment

Output 2015 69% 69% 80% 85% 90% 95%

LMIS

quarterly

reports

Quarterly



source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20


diagnostic and

treatment units

reporting no stock

outs of TB lab

supplies in the last

3 months before

assessment

Output 2015 Unknown >90% >90% >95% >95% >95%

LMIS

quarterly

reports

Quarterly

Strategic intervention 4.7: Strengthen M&E systems for tracking performance and measuring outcomes and impacts to guide decision-making.


source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20


districts submitting

timely, complete

reports according

to national

guidelines (factor =

timeliness x

completeness)

Output 2015 Unknown Unknown >90% >90% >90% >90% NTLP/DHI

S2 Quarterly


Strategic intervention 4.8: Implement NTLP-led TB research agenda in collaboration with the Uganda TB research community.


source Frequency

Year Value 2015/16 2016/17 2017/18 2018/19 2019/20

4.8.1. Operational

research projects

conducted and

findings

disseminated

Output 2015 4 4 6 10 14 18 NTLP

report Annual


Leprosy Goal: To reduce the incidence of Grade 2 disabilities (Gr2D) among new leprosy cases from 2.3 per million population in 2014 to less

than 1 per million population by 2019/20.

1. To increase the proportion of leprosy endemic districts with annual plans containing leprosy activities aligned to NSP from 50% in 2014 to over

95% in 2020.

2. To reduce the proportion of new child leprosy cases with Grade 2 disabilities from 12% in 2014 to zero by 2020.

3. To increase Multi Bacillary MDT completion from 91% in 2014 to 95% in 2020.

4. To increase the proportion of persons affected by leprosy with insensitive feet who are provided protective footwear from 50% in 2014 to 100% in

2020.

5. To increase the proportion of persons affected by leprosy accessing self-care support from less than 5% in 2014 to 35% in 2020.


Data source Frequency Year Value 2015 2016 2017 2018 2019 2020

L.1 Prevalence of

grade 2 disabilities

among new

cases/1,000,000

population

Impact 2015 2.3 per

million 1.9 1.7 1.4 1.1 0.9

< 1 per

1 million

Leprosy

quarterly

reports

Annual

L.2 Percentage of

new cases of

leprosy with grade

2 disabilities

Outcome 2015 33% 30% 28% 23% 19% 16% 15%

Leprosy

quarterly

reports

Quarterly


Strategic intervention L1. Increase the proportion of leprosy endemic districts with annual plans containing leprosy activities aligned to NSP

from 50% in 2014 to over 95% in 2020



L.1.1 Percentage of

leprosy endemic

districts with

annual plans

containing leprosy

activities aligned to

NSP

Output 2015 50% 60% 80% 90% >95% >95% >95% Supervisory

reports Annual

Strategic intervention L.2. Reduce the proportion of new child leprosy cases with Grade 2 disabilities from 12% in 2014 to zero by 2020.



L.2.1 Percentage

of new child

leprosy cases with

Grade 2

disabilities from

12% in 2014 to

zero by 2020.

Output 2014 12% 12% 12% 9% 6% 3% 0% NTLP quarterly

reports Quarterly


Strategic intervention L.3. Increase the Multi Bacillary MDT completion from 91% in 2014 to 95% by 2019/20.



L.3.1 Percentage

of MB leprosy

cases that

successfully

complete

prescribed MDT

Outcome 2015 83% 85% 87% 90% 92% 95% >95%

Leprosy

quarterly

reports

Quarterly

Strategic intervention L.4. Increase the proportion of persons affected by leprosy with insensitive feet who are provided protective footwear

from 50% in 2014 to 100% in 2020.



L.4.1 Percentage of

leprosy affected

persons in need of

protective footwear

actually provided

Output 2015 50% 60% 70% 80% 90% 100% 100%

Leprosy

quarterly

reports

Quarterly

Strategic intervention L.5. To increase proportion of persons affected by leprosy accessing self-care support from <5% in 2014 to 35% in 2020.



L.5.1 Percentage of

persons affected by

leprosy accessing

self-care support

Outcome 2014 5% 5% 5% 10% 15% 25% 35%

Leprosy

quarterly

reports

Quarterly


Table 3: Indicator definitions

Indicator Definition Numerator Denominator

1.0 Incidence Rate

Number of all new and relapse TB

patients per 100,000 population per

year determined from longitudinal

survey

NA NA

1.1. Notification rate of

incident TB cases (CNR) per

100,000 population

Number of notified new and relapse TB

patients in a calendar year per 100,000

population

Number of notified new and

relapse TB patients in a calendar

year

Number of inhabitants

1.2. Treatment success rate for

incident TB cases

Number of notified new and relapse TB

patients who are cured plus those who

completed treatment as a percentage

of all notified new and relapse TB

patients in a given period


relapse TB patients who are cured

plus those who completed

treatment

All notified new and relapse TB


1.3. Cure rate among new PBC

Number of New Bacteriologically

Confirmed (P-BC) patients declared

Cured as a percentage of total

Number of new P-BC cases

Number of new P-BC cases

with cured treatment outcome

Total Number of new P-BC

cases

1.4. Treatment success rate

among all forms of TB

Number of notified TB patients (all

forms) who are cured plus those who

completed treatment as a percentage

of notified TB patients (all forms) in a

given period


forms) who are cured plus those

who completed treatment

Notified TB patients (all forms) in a

given period

1.5. Case fatality rate among all

forms of TB


forms) who died while on TB treatment

as a percentage of notified TB patients

(all forms) in a given period


forms) who died while on TB

treatment


given period



1.6. Loss to follow up rate

among all forms of TB


forms) who were lost to follow up

while on TB treatment as a percentage

of notified TB patients (all forms) in a

given period


forms) who were lost to follow up

while on TB treatment


given period

1.1.1. Percentage of children

aged younger than 15 years

among all forms of incident

(new and relapse) TB cases

notified

Number of notified incident (new and

relapse) TB patients younger than 15

years of age in the period under review

as a percentage of the total number

notified (new + relapse) TB patients

Number of notified new & relapse

TB patients younger than 15 years

of age in the period under review


relapse TB patients in period under

review

1.2.1. Number of

bacteriologically confirmed

patients notified

Number of bacteriologically confirmed

patients (new and relapse) TB patients

in the period under review

NA NA

1.2.2. Percentage of new and

relapse TB Patients tested

using WHO recommended

rapid tests at time of diagnosis

Patients tested using a WHO

recommended

rapid test at the time of diagnosis,

divided by the

total number of new and relapse TB

patients, expressed as a percentage

Number of patients tested using a

WHO recommended rapid test at

the time of diagnosis

Total number of new and relapse

TB patients

1.2.3. Drug susceptibility

testing (DST) coverage (%)

Number of TB patients with DST results

for at least rifampicin divided by the

total number of notified (new and

retreatment) cases in the same year,

expressed as a percentage.

DST coverage includes results from

molecular (e.g. Xpert MTB/RIF) as well

as conventional phenotypic DST

results.

Number of TB patients (new and

retreatment) with DST results for at

least rifampicin

Total number of notified (new and

retreatment) cases in the same

year



1.2.4 Percentage of labs

participating in external quality

assurance (EQA).

Number of laboratories participating in

EQA (defined as sending slides for

blind rechecking) as a percentage of

the total number of laboratories with

smear microscopy

Number of laboratories

participating in EQA (defined as

sending slides for blind

rechecking)

Number of laboratories with smear

microscopy

1.2.5. Percentage of high false

negative reported in diagnostic

and treatment units.

Number of false negative slides (slide

read as negative when the controller

reads positive 1, 2 or 3) as a

percentage of number of all slides

rechecked

Number of false negative slides

(slide read as negative when the

controller reads positive 1, 2 or 3)

Number of slides rechecked

1.3.1. TB Treatment coverage

(%)

Number of new and relapse cases that

were notified and treated, divided by

the estimated number of incident TB

cases in the same year,


Number of new and relapse cases

notified and treated in a given year

Estimated number of incident TB

cases in the same year

1.3.2. Treatment coverage new

TB drugs (%)

Number of TB patients treated with

regimens that include new (endorsed

after 2010) TB drugs, divided by the

number of notified patients eligible for

treatment with new TB drugs,


Number of TB patients treated with

regimens that include new

(endorsed after 2010) TB drugs

The number of notified patients

eligible for treatment with new TB

drugs

1.4.1. Percentage of TB cases

(all forms) notified in DTUs

who were referred by the

village health team or CSO.

Number of TB cases (all forms) notified

in DTUs who were referred by

VHT/CSO as a percentage of all TB

cases (all forms) notified

Number of TB cases (all forms)

notified in DTUs referred by

VHT/CSO

Number of all TB cases (all forms)

notified

1.4.2. Contact investigation

coverage

Number of contacts of people with

bacteriologically-confirmed TB who

were evaluated for TB, divided by the


bacteriologically-confirmed TB

who were evaluated for TB

Total number of contacts of people

with bacteriologically confirmed TB



number eligible, expressed as a

percentage.


coverage among PBC-TB

Number of PBC-TB patients whose

contacts have been traced and

investigated for TB as a percentage of

all PBC-TB patients diagnosed in a

given period

Number of PBC-TB patients whose

contacts have been traced and

investigated for TB

PBC-TB patients diagnosed in a

given period

1.4.4. Number of close contacts

(<5years) of PTB patients

provided IPT

Number of close contacts (<5years) of

PTB patients provided IPT NA NA

1.4.5. Latent TB treatment (IPT)

coverage (<5years contacts of

PTB patients)

Number of children younger than 5

years who are household contacts of

cases started on latent TB infection

(LTBI) treatment, divided by the

number eligible for treatment,

expressed as a

percentage

Number of children younger than

5 years who are household

contacts of cases started on LTBI

treatment

Total number of children younger

than 5 years eligible for LTBI

1.5.1 Proportion of mapped

CSOs that are implementing TB

control activities

Number of mapped CSOs that are

implementing TB control activities as a

percentage of all CSO’s registered with

URSB


implementing TB control activities

Total number of CSO’s registered

with URSB

1.5.2 Proportion of mapped CSO’s

reporting using recommended

tools


reporting using recommended TB tools

as a percentage of mapped CSO’s



reporting using recommended TB

tools





1.5.3 Proportion of mapped CSOs

trained in TB management


trained in TB management as a

percentage of mapped CSO’s



trained in TB management



1.6.1. Percentage new

prisoners screened for TB

(entry screening)

Number of new prisoners screened for

TB (entry screening) as a percentage of

number of all prisoners entering the

prison system

Number of new prisoners screened

for TB by entry screening

Number all prisoners entering the

prison system

1.6.2. Number bacteriological

confirmed TB in new prisoners

Number bacteriological confirmed TB

in new prisoners found through entry

screening

NA NA

1.7.1. Number of private for-

profit and private not-for-

profit health facilities

accredited to function as

diagnostic and treatment units

(DTUs)

Number of private for-profit and

private not-for-private health facilities

functioning as DTUs

NA NA

1.8.1. Treatment success rate

for incident TB cases on first-

line drugs in cities and

municipalities

Number of bacteriologically confirmed

patients (new and previously treated

relapse) TB patients in the period

under review successfully treated

(cured and treatment completed) as a

percentage of the total number

bacteriologically confirmed patients

starting First Line Drugs (FLD) in cities

and municipalities

Number of bacteriologically

confirmed patients (new and

previously treated relapse) TB

patients in the period under review

successfully treated (cured and

treatment completed) in cities and

municipalities

Number bacteriologically

confirmed patients starting first-

line drugs in cities and

municipalities




coverage in cities and

municipalities


bacteriologically-confirmed TB in cities

and municipalities who were evaluated

for TB, divided by the number eligible,



bacteriologically-confirmed TB in

cities and municipalities who were

evaluated for TB

Total number of contacts of people

with bacteriologically confirmed TB

in cities and municipalities

1.8.3. Number of close contacts

(<5years) of PTB patients

provided isoniazid preventive

therapy (IPT) in cities and

municipalities

Number of close contacts (<5years) of

PTB patients provided IPT in cities and

municipalities

NA NA

1.8.4. Latent TB treatment

(isoniazid preventive therapy)

coverage (<5years contacts of

PTB patients) in cities and

municipalities

Number of children younger than 5

years who are household contacts of

cases started on LTBI treatment in

cities & municipalities, divided by the


expressed as a percentage

Number of children younger than

5 years who are household

contacts of cases started on LTBI

treatment in cities and

municipalities

Total number of children younger

than 5 years eligible for LTBI in

cities and municipalities

2.1. Percentage of TB patients

co-infected with HIV who

started on and/or continued

anti-retroviral therapy (ART)

Number of HIV-positive TB patients

started on and/or continued ART as a

percentage of all HIV+ TB patients

notified in the period under review

Number of HIV-positive TB

patients on ART in the period

under review

Number of all HIV+ TB patients


2.1.1. Percentage of TB/HIV

joint planning meetings held

Number of TB/HIV joint planning

meetings held as a percentage of the

number of planned meetings

Number of TB/HIV joint planning

meetings held Number of planned meetings

2.2.1. Percentage of TB (HCIV

and above) and HIV clinics

providing TB/HIV services in an

integrated manner

Number of TB (HCVI and above) and

HIV clinics implementing one-stop

centre model for co-infected TB

patients as a percentage of total

number of ART accredited facilities

Number of TB (HCVI and above)

and HIV clinics implementing one-

stop centre model for co-infected

TB patients

Total number of TB (HCVI and

above) and HIV clinics



2.3.1. Percentage of registered

TB patients with documented

HIV status

Number of TB patients with known HIV

status as a percentage of all notified TB

patients in the period under review

Number of TB patients with known

HIV status Number of all notified TB patients

2.3.2. Percentage of HIV-

positive TB patients who

started on and/or continued

co-trimoxazole preventive

treatment (CPT)

Number of HIV-positive TB patients

treated with CPT as a percentage of all

HIV+ TB patients notified in the period

under review

Number of HIV-positive TB

patients treated with CPT in the

period under review

Number of all HIV+TB patients


2.4.1. Percentage of people

living with HIV who were newly

enrolled in HIV care and

screened for TB

Number of people living with HIV who

were newly enrolled in HIV care and

screened for TB, divided by the total

number of people living with HIV

eligible for screening for TB, expressed

as a percentage

Number of people living with HIV

who were newly enrolled in HIV

care and screened for TB in a given

period

Total number of people living with

HIV who were newly enrolled in

HIV care in the same period

2.4.2. Latent TB treatment (IPT)

coverage among people living

with HIV newly enrolled in HIV

care


newly enrolled in HIV care started on

LTBI treatment (IPT) divided by the




newly enrolled in HIV care started

on LTBI treatment (IPT)

Total number of people living with

HIV newly enrolled in HIV care

eligible for LTBI (IPT)

2.5.1. Number of health

workers diagnosed with TB in

the last year

Number of health workers diagnosed

with TB in the last year at health

facilities

NA NA

2.5.2. Percentage of prisoners

screened for TB in the last year

Number of prisoners screened at least

once for TB in a given period divided

by total number of prisoners in the

same period, expressed as a

percentage

Number of prisoners screened at

least once for TB in a given period

Number of prisoners screened at

least once for TB in the same

period



3.1. Number and percentage of

detected MDR/RR-TB patients

among estimated MDR/RR TB

cases

Number of detected MDR/RR-TB

patients as a percentage of estimated

MDR/RR-TB cases

Number of detected MDR/RR-TB

patients

Number of estimated MDR/RR-TB

patients in the population

3.2. Treatment success rate for

MDR/RR-TB cases

Number of MDR/RR-TB patients who

have cured plus those who completed

treatment as a percentage of total

number of MDR/RR TB patients started

on treatment in a given period

Number of MDR/RR-TB patients

who have cured plus those who

completed treatment

Total number of MDR/RR TB

patients started on treatment in a

given period

3.1.1. Percentage of previously

treated TB patients tested for

MDR TB with documented

Genexpert MTB/Rif or culture

result

Number of previously treated TB

patients tested for MDR TB with

documented Genexpert MTB/Rif or

culture result as a percentage of the

total number of previously treated TB


Number of previously treated TB

patients tested for MDR TB with

documented Genexpert MTB/Rif or

culture result

Total number of previously treated

TB patients in a given period

3.1.2. Percentage of close

contacts of MDR/RR-TB

patients traced and screened

for TB at least once

Percentage of close contacts of

MDR/RR-TB patients traced and

screened for TB at least once

Number of close contacts of

MDR/RR-TB patients traced and

screened for TB at least once

Number of close contacts of

MDR/RR-TB patients

3.2.1. Number of confirmed

MDR/RR-TB cases started on

MDR/RR-TB treatment

Number of confirmed MDR/RR-TB

cases started on MDR/RR-TB treatment NA NA

3.3.1 Number of functional

MDR/RR-TB treatment

initiation sites

Number of functional MDR/RR-TB

treatment initiation sites NA NA



3.4.1. Number of health

workers diagnosed with

MDR/RR-TB in the previous

one year

Number of health workers diagnosed

with MDR/RR-TB in the previous one

year

NA NA

3.5.1. Percentage of MDR/RR-

TB treatment facilities

submitting timely and

complete reports according to

national guidelines

Number of MDR/RR-TB treatment

facilities submitting timely and

complete reports as a percentage of

total number of DR-TB treatment

facilities in a given period

Number of MDR/RR-TB treatment

facilities submitting timely and

complete reports

Total number of MDR/RR-TB

treatment facilities in the same

period under review

4.1.1. Percentage of the NTLP

annual budget funded by

government

Percentage of the NTLP annual budget

funded by government

Annual contribution from the

Government of Uganda

Annual NTLP budget per the

National Strategic Plan

4.1.2. Percentage of TB

affected households that

experience catastrophic costs

due to TB

Number of people treated for TB (and

their households) who incur

catastrophic costs (direct and indirect

combined), divided by the total

number of people treated for TB.

Number of people treated for TB

(and their households) who incur

catastrophic costs (direct and

indirect combined)

Total number of people treated for

TB.

4.2.1. New TB and leprosy

community groups active in TB

and leprosy care

Number of new TB and leprosy

community groups active in TB and

leprosy care

NA NA

4.3.1. Proportion of filled

positions in the NTLP human

resources structure

Number of filled positions in the NTLP

human resources structure as a

percentage of the number in the NTLP

human resources structure

Number of filled positions in the

NTLP human resources structure

Total number of positions in the

NTLP human resources structure

4.5.1. Percentage of initial loss

to follow up

Number of diagnosed TB patients who

do not initiate treatment divided by

total number of diagnosed TB patients

Number of diagnosed TB patients

who do not initiate treatment in a

given period of time

Total number of diagnosed TB

patients in the same period of time



in the same period of time, expressed

as a percentage

4.5.2. Loss to follow up rate for

notified cases

Number of diagnosed TB patients who

do not initiate treatment plus those

who initiate treatment but do not

complete treatment divided by total

number of diagnosed TB patients in

the same period of time, expressed as

a percentage

Number of diagnosed TB patients

who do not initiate treatment plus

those who initiate treatment but

do not complete treatment in a

given period of time

Total number of diagnosed TB

patients in the same period of time

4.6.1. Percentage of treatment

units reporting no stock-outs

of anti-TB medicines in the last

3 months before assessment

Number of health facilities reporting

no stock-outs of anti-TB medicines in

the last 3 months before assessment as

a percentage of the number of health

facilities assessed

Number of health facilities

reporting no stock-outs of anti-TB

medicines in the last 3 months

before assessment

Total number of health facilities

assessed

4.6.2. Percentage of diagnostic

and treatment units (DTUs)

reporting no stock-outs of TB

lab supplies in the last 3

months before assessment

Percentage of DTUs reporting no

stock-outs of TB lab supplies in the last

3 months before assessment

Number of DTUs reporting no

stock outs of TB laboratory

supplies in the last 3 months

before assessment

Total number of DTUs assessed

4.7.1. Percentage of districts

submitting timely and

complete reports according to

national guidelines

Number of districts submitting timely

and complete reports according to

national guidelines (factor = timeliness

x completeness) as a percentage of

number of district submitting reports

Number of districts submitting

timely and complete reports

according to national guidelines

(factor = timeliness x

completeness)

Total number of district submitting

reports

4.8.1. Operational research

projects conducted and

findings disseminated

Number of operational research

projects conducted and findings

disseminated

NA NA



L.1 Prevalence of grade 2

disabilities among new

cases/1,000,000 population

Number of leprosy patients with grade

2 disabilities among new

cases/1,000,000 population

Number of leprosy patients with

grade 2 disabilities among new

cases

population

L.2 Percentage of new cases

of leprosy with grade 2

disabilities

Number of leprosy patients with grade

2 disabilities as a percentage of new

leprosy cases

Number of leprosy patients with

grade 2 disabilities Total number of new leprosy cases

L.1.1 Percentage of leprosy

endemic districts with annual

plans containing leprosy

activities aligned to NSP

Number of leprosy endemic districts

with annual plans containing leprosy

activities aligned to NSP as a

percentage of the number of leprosy

endemic districts

Number of leprosy endemic

districts with annual plans

containing leprosy activities

aligned to NSP

Total number of leprosy endemic

districts

L.2.1 Percentage of new child

leprosy cases with Grade 2

disabilities

Number of new child leprosy cases

with Grade 2 disabilities as a

percentage of total number of leprosy

cases with grade 2 disabilities

Number of new child leprosy cases

with Grade 2 disabilities

Total number of leprosy cases

with grade 2 disabilities

L.3.1 Percentage of Multi

Bacillary leprosy cases that

successfully complete

prescribed MDT

Number of Multi Bacillary leprosy

cases that successfully complete

leprosy MB treatment as a percentage

of total number of MB leprosy cases

Number of MB leprosy cases that

successfully complete leprosy MB

treatment

Total number of MB leprosy cases

L.4.1 Percentage of leprosy

affected persons in need of

protective footwear actually

provided

Number of leprosy affected persons in

need of protective footwear actually

provided as a percentage of the

people in need of protective footwear

Number of leprosy affected

persons in need of protective

footwear actually provided

Total number of leprosy affected

persons in need of protective

footwear

L.5.1 Percentage of persons

affected by leprosy accessing

self-care support

Number of persons affected by leprosy

accessing self-care support as a

percentage of total number of leprosy

affected persons

Number of persons affected by

leprosy accessing self-care

support

Total number of leprosy affected

persons


Table 4: List of indicators to be included into DHIS2

Indicator name Denominator Description Numerator Description Multiplier factor

Expected TB cases 100000 National projected Population 234

Expected MDR-TB cases (All New TB cases X 0.014) +( (Total all - total New) X 0.121)

TB Case Detection Rate per 100,000 Pop National projected Population

New + Relapse bacteriologically confirmed PTB (P-

BC) cases 100000

TB Case notification for all TB forms (new &

relapse) per 100,000 population National projected Population All New + all Relapse TB cases 100000

TB prevalence rate per 100,000 Pop National projected Population Total number of TB cases 100000

Percentage of TB patients on DOT

Total number of all TB cases

registered in the same period

Number of patients on DOT(Facility + Community

based DOT) 100

Percentage of TB patients tested for HIV

Total number of all TB cases

registered in the same period Number of TB cases tested for HIV 100

Percentage of TB/HIV co-infected patients Total Number of TB cases tested for HIV Number of TB cases tested HIV positive 100

Percentage of HIV-positive TB patients treated with Cotrimoxazole prophylaxis (CPT)

Number of TB cases tested HIV positive

Number of HIV-positive TB patients treated with Cotrimoxazole prophylaxis (CPT) 100



Percentage of HIV-positive TB patients

who started or continued ART during TB treatment Number of TB cases found with HIV

Number TB/HIV co-infected patients who started or

continued ART 100

Proportion of new childhood (0-14 years) TB cases All New + all Relapse TB cases All New + all Relapse 0 - 14 years old TB cases 100

Proportion of <5 years contacts started on IPT Number of < 5 Years contacts Number of < 5 Years contacts started on IPT 100

Treatment success rate among new P-BC cases Total Number of new P-BC cases Number of new P-BC cases with cured + completed treatment outcome in the period 100

Cure rate among new P-BC cases Total Number of new P-BC cases Number of new P-BC cases with cured treatment outcome 100

Death rate among new P-BC cases Total Number of new P-BC cases Number of new P-BC cases with died treatment outcome 100

Lost to Follow Up rate among new P-BC cases Total Number of new P-BC cases Number of new P-BC cases with Lost to Follow Up treatment outcome 100

Failure rate among new P-BC cases Total Number of new P-BC cases

Number of new P-BC cases with Failure treatment

outcome 100

Proportion of Not Evaluated among new P-BC cases Total Number of new P-BC cases Number of new P-BC cases with Not evaluated treatment outcome 100

Treatment success rate among new P-CD and EPTB cases

Total number of new P-CD + EPTB cases

Number of new P-CD + EPTB cases with completed treatment outcome 100

Percentage of MDR-TB with Laboratory Confirmed

DST results

Total number of MDR-TB cases

diagnosed

Number of MDR-TB patients with Laboratory

confirmed results



Percentage of MDR-TB with documented sputum negative at 6 months of treatment

Total MDR-TB cases started on treatment

Number of MDR-TB patients with culture negative results at 6 months of treatment 100

Percentage of MDR-TB who are lost to follow-up before completing 6 months of treatment


Number of MDR-TB patients with lost to follow up out come within 6 months of treatment 100

Percentage of MDR-TB with unknown culture results at 6 months of treatment


Number of MDR-TB patients with no results at 6 months of treatment 100

Percentage of MDR-TB who died before completing

6 months of treatment

Total MDR-TB cases started on

treatment

Number of MDR-TB patients with Died out come

within 6 months of treatment 100

Percentage of MDR-TB with documented sputum

positive at 6 months of treatment

Total MDR-TB cases started on

treatment

Number of MDR-TB patients with culture positive

result at 6 months of treatment 100

Treatment success rate among MDR-TB cases Total Number of MDR-TB cases Number of MDR-TB cases with cured + completed treatment outcome in the period 100

Cure rate among Bacteriologically confirmed MDR-TB cases

Total Number of Bacteriologically confirmed MDR-TB cases

Number of Bacteriologically confirmed MDR-TB cases with cured treatment outcome 100

Death rate among MDR-TB cases Total Number of MDR-TB cases Number of MDR-TB cases with died treatment outcome 100

Lost to Follow Up rate among MDR-TB cases Total Number of MDR-TB cases

Number of MDR-TB cases with Lost to Follow Up

treatment outcome 100

Failure rate among MDR-TB cases Total Number of MDR-TB cases Number of MDR-TB cases with Failure treatment outcome 100



Proportion of Not Evaluated among MDR-TB cases Total Number of MDR-TB cases Number of MDR-TB cases with Not evaluated treatment outcome 100

Percentage of MB cases among new leprosy cases Total number of new leprosy cases Number of MB cases among new leprosy cases 100

Leprosy Case Detection Rate per 100,000 Pop National projected Population New + Relapse Leprosy cases 100000

Percentage of leprosy with WHO Disability grade 1 and 2 among new leprosy cases

Total number of new + Relapse leprosy cases

Number of new Leprosy with WHO disability grading 1 or 2 100

Leprosy treatment completion rate Total number of Leprosy cases started on treatment

Total number of Leprosy cases released from treatment 100


3. Narrative of the Operational, Budget and Technical Assistance

Plan

The operational, budget and technical assistance plan, detailed in the Excel file

operational.TA.nsp.Uganda, corresponds to the enumerated goals, objectives, strategic

interventions and activities in the National Strategic Plan (NSP) and the Monitoring and

Evaluation (M&E) Plan. The NSP divides the TB and leprosy sections, but in the operational,

budget and technical assistance plan, the leprosy section follows TB and uses the NSP

numbering system for easy reference. The TB objectives are numbered 1 to 4, while the leprosy

objectives are numbered L1 to L5.

The NTLP prepared the operational plan in May to July 2014 and updated it during December

2016 to February 2017, although NSP implementation started in July 2015. The operational plan

outlines activities for each strategic intervention and details implementation levels (national,

regional, district and health facility), corresponding indicators, start and end dates, and the total

budget for each activity. Activities for July 2015 to June 2017 are planned by quarter.

The NTLP will need to review and adapt the operational plan, if necessary, on an annual basis. To

carry out the operational plan, the NTLP identified potential funding sources, based on the

partner mapping (attached to the NSP) conducted May to July 2014 and December 2016 to

February 2017. However, many partners could not guarantee continuation of funding after the

end date of their project/ program implementation.

The NTLP prepared and revised the budget using the One Health Tool and the WHO planning

and budgeting tool, both of which complement each other. Developed by partners to assist

countries in health sector planning and budgeting, the One Health Tool uses slightly different

intervention categories and therefore the operational plan contains the budget necessary per

activity line.

While the budget for leprosy includes leprosy-specific activities, many of the leprosy costs are

related to NTLP functioning and therefore covered under Objective 4 in the TB section of the

NSP.

The budget does not take depreciation and inflation into account.

HIV-related medicines and supplies, such as HIV tests and antiretroviral therapy for TB patients,

are not included in this NTLP budget.

Each activity lists the type of technical assistance (TA) needed. While the NTLP may source TA

from local or international partners, depending on the assessment at the time of developing this

NSP, the NTLP should recruit local TA, whenever possible. The NTLP should review TA needs and

availability every year and revise the TA plan as necessary.

Documents

UGANDA NATIONAL TUBERCULOSIS AND LEPROSY CONTROL …E Plan... · necessitated revisions to the current NTLP National Strategic Plan (NSP) 2015/16 to 2019/20. Accordingly, the NTLP